NCT00990704

Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism

Phase II, Open Study, Exploratory Examination of Efficacy and Safety of Paricalcitol Injection and Maxacalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 47 (actual)
• Sponsor: Abbott · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

This study is a exploratory comparison of the efficacy and safety of paricalcitol injection with maxacalcitol injection in chronic kidney disease participants receiving hemodialysis with secondary hyperparathyroidism.

Conditions

• Secondary Hyperparathyroidism
• Hemodialysis

Interventions

Type	Name	Description
DRUG	paricalcitol	Intravenous administration 3 times a week immediately before completion of dialysis
DRUG	maxacalcitol	Intravenous administration 3 times a week immediately before completion of dialysis

Timeline

• Start date: 2009-10-01
• Primary completion: 2010-05-01
• Completion: 2010-05-01
• First posted: 2009-10-07
• Last updated: 2011-07-11
• Results posted: 2011-06-17

Locations

14 sites across 1 country: Japan